Patent US10603288

Use of cannabinoids in the treatment of epilepsy
[+] Show Details

US10603288

1. A method of treating seizures in a patient with treatment-resistant Lennox-Gastaut syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD, and wherein the CBD is administered at a dose of 5 mg/kg/day, and then the dose is increased by 2 to 5 mg/kg increments. (12) (0)

2. The method of claim 1, wherein the administering reduces total convulsive seizure frequency. (0)

3. The method of claim 1, wherein the dose of the CBD is increased to about 10 mg/kg/day to about 25 mg/kg/day. (0)

4. The method of claim 1, wherein the dose of the CBD is increased to about 15 mg/kg/day to about 25 mg/kg/day. (0)

5. The method of claim 1, wherein the dose of the CBD is increased to about 25 mg/kg/day. (0)

6. The method of claim 1, wherein the dose of the CBD is increased to about 10 mg/kg/day. (0)

7. The method of claim 1, wherein the dose of the CBD is increased to about 12 mg/kg/day. (0)

8. The method of claim 1, wherein the dose of the CBD is increased to about 14 mg/kg/day. (0)

9. The method of claim 1, wherein the dose of the CBD is increased to about 15 mg/kg/day. (0)

10. The method of claim 1, wherein the dose of the CBD is increased to about 18 mg/kg/day. (0)

11. The method of claim 1, wherein the dose of the CBD is increased to about 20 mg/kg/day. (0)

12. The method of claim 1, further comprising administering clobazam to the patient. (0)

15. The method of claim 1, wherein the dose of the CBD is increased to about 10 mg/kg/day to about 20 mg/kg/day. (0)

13. A method of reducing convulsive seizure frequency in a patient with treatment-resistant Lennox-Gastaut syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD, wherein the dose of the CBD is 5 mg/kg/day to 25 mg/kg/day. (0)

14. A method of reducing convulsive seizure frequency in a patient with treatment-resistant Dravet syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD, wherein the dose of the CBD is 5 mg/kg/day to 25 mg/kg/day. (0)

16. A method of treating seizures in a patient with treatment-resistant Dravet syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD, and wherein the CBD is administered at a dose of 5 mg/kg/day, and then the dose is increased by 2 to 5 mg/kg increments. (12) (0)

17. The method of claim 16, wherein the administering reduces total convulsive seizure frequency. (0)

18. The method of claim 16, wherein the dose of the CBD is increased to about 10 mg/kg/day to about 25 mg/kg/day. (0)

19. The method of claim 16, wherein the dose of the CBD is increased to about 15 mg/kg/day to about 25 mg/kg/day. (0)

20. The method of claim 16, wherein the dose of the CBD is increased to about 25 mg/kg/day. (0)

21. The method of claim 16, wherein the dose of the CBD is increased to about 10 mg/kg/day. (0)

22. The method of claim 16, wherein the dose of the CBD is increased to about 12 mg/kg/day. (0)

23. The method of claim 16, wherein the dose of the CBD is increased to about 14 mg/kg/day. (0)

24. The method of claim 16, wherein the dose of the CBD is increased to about 15 mg/kg/day. (0)

25. The method of claim 16, wherein the dose of the CBD is increased to about 18 mg/kg/day. (0)

26. The method of claim 16, wherein the dose of the CBD is increased to about 20 mg/kg/day. (0)

27. The method of claim 16, further comprising administering clobazam to the patient. (0)

28. The method of claim 16, wherein the dose of the CBD is increased to about 10 mg/kg/day to about 20 mg/kg/day. (0)

View Abstract and Specification Size

PDF with Images and Document Face >

Full Text Publication >

Patent US10603288

Use of cannabinoids in the treatment of epilepsy

Patent Matrix® Search